Bristol-Myers Squibb received approval from the FDA for Nulojix (belatacept) to prevent acute rejection in adult patients who have had a kidney transplant. Nulojix is a selective T-cell costimulation blocker. The drug helps to prevent organ rejection after a kidney transplant. Without immunosuppression, the body can reject a transplanted organ because the immune system recognizes the new organ as foreign (transplant rejection). Nulojix was evaluated in two open-label, randomized, multicenter, ...